Dupilumab meets in atopic dermatitis trial

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and partner Sanofi (Euronext:SAN; NYSE:SNY) said subcutaneous dupilumab ( SAR231893, REGN668) met the primary endpoint in a Phase IIb trial to treat moderate to severe atopic dermatitis. The endpoint was improvement in the mean percent change in Eczema Area and Severity Index (EASI) score from baseline to week 16 vs. placebo.

Data from two Phase IIa trials and two Phase I trials of dupilumab to treat moderate to severe atopic dermatitis were published in the New England Journal of Medicine. The data showed dupilumab as monotherapy or in combination with topical glucocorticoids was associated with improvements in skin lesions and itching. ...